Cognition Therapeutics, Inc.
$1.42
+14%Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, a sigma-2 receptor antagonist, which is in Phase II clinical trial for the treatment of mild-to-moderate Alzheimer's disease, as well as has completed Phase I clinical trial to treat early-stage Alzheimer's disease; in Phase II clinical trial for the treatment of dementia with Lewy bodies (DLB); and in preclinical trial to treat dry age-related macular degeneration (AMD). The company is also developing CT2168 for the treatment of synucleinopathies, which include DLB and Parkinson's disease; and CT2074 to treat dry AMD. Cognition Therapeutics, Inc. was incorporated in 2007 and is headquartered in Purchase, New York.
At a Glance
Live SnapshotIntrinsic Alpha Methodology
Thesis Lenses
Signal
Medium confidenceValuation multiple is compressed (P/E -4.4).
Valuation inputs: P/E -4.4, earnings yield N/A, momentum +13.6%.
If multiples stay elevated while momentum fades, downside repricing risk rises.
Driver
High confidenceReturn profile is soft (ROE -68.5%, ROIC -1.4%).
Profitability stack: net margin 0.0%, ROE -68.5%, ROIC -1.4%.
Quality deterioration often appears in margins before it shows up in headline EPS.
Risk
High confidenceRisk profile is balanced but has notable pressure points to monitor.
Risk factors: liabilities/assets +29.2%, momentum +13.6%, net margin 0.0%.
Higher leverage with weak momentum and thin margins can amplify drawdown severity.
Cognition Therapeutics, Inc. Market vs Earnings Trajectory
Loading price and EPS data...
Cognition Therapeutics, Inc. Fair Value Envelope
No Revenue Data
CGTX has not reported any revenue values in the available annual periods.
Cognition Therapeutics, Inc. Profit Bridge
Profitability Analysis
No Gross Profit Margin Data
CGTX has not reported any gross profit margin values in the available annual periods.
No Operating Profit Margin Data
CGTX has not reported any operating profit margin values in the available annual periods.
No Net Profit Margin Data
CGTX has not reported any net profit margin values in the available annual periods.
Cognition Therapeutics, Inc. Cash Conversion Engine
Cash Flow Quality Analysis
FCF Conversion Rate
Excellent cash generation. The company converts earnings to cash at or above 100%, indicating high-quality earnings.
FCF Growth Trend
Steady FCF growth indicates consistent cash generation improvement. On a positive trajectory.
Working Capital Impact
Minimal working capital impact on FCF. Changes in operating assets and liabilities well-managed.
Cash Flow Quality Insight
Exceptional cash generation: High-quality earnings converting to growing free cash flow. The company demonstrates strong pricing power, efficient operations, and disciplined capital allocation.
Cognition Therapeutics, Inc. Funding & Solvency Profile
Financial Health Analysis
Current Ratio
Excellent liquidity position. The company can easily cover its short-term obligations with substantial cushion.
Debt-to-Equity Ratio
Conservative capital structure. The company relies primarily on equity financing, indicating low financial risk.
Working Capital
Strong working capital position provides significant operational flexibility and financial cushion.
Asset Composition
Asset-light business model with high liquidity. Majority of assets are easily convertible to cash.
Financial Health Insight
Strong financial foundation: Excellent liquidity combined with conservative leverage suggests the company is well-positioned to weather economic uncertainties and fund growth opportunities.
Cognition Therapeutics, Inc. Street Expectations Map
No Target Data
No analyst price targets available for cgtx.
Cognition Therapeutics, Inc. Insider Positioning
During the last 12 months, insiders have purchased $32K and sold $42K worth of CGTX shares, resulting in $10K of net selling activity.
3 Months
29.2K
32.49K
0
0.00
+32K
+$32K
3-6 Months
0
0.00
0
0.00
+0
+$0
6-9 Months
0
0.00
7.7K
6.49K
-6K
-$6K
9-12 Months
0
0.00
53.0K
35.55K
-36K
-$36K
Top Buyers
Doyle John Brendan
Officer: Chief Financial Officer
$11K
Caggiano Anthony
Officer: Chief Medical Officer
$11K
Ricciardi Lisa
Director, Officer: Ceo & President
$10K
Top Sellers
Ricciardi Lisa
Director, Officer: Ceo & President
$16K
Caggiano Anthony
Officer: Chief Medical Officer
$14K
Fletcher Aaron G.L.
Director, 10 Percent Owner:
$6K
Doyle John Brendan
Officer: Chief Financial Officer
$6K
Insider Activity Analysis
Net Insider Sentiment
Slightly bearish with $10K net selling. Selling modestly exceeds buying, which could be routine diversification rather than concern.
Buy/Sell Ratio
Moderately negative ratio. Selling is roughly double the buying, which may be routine or signal caution.
Recent Trend (3 Months)
Very strong recent buying momentum. Recent insider purchases significantly outpace sales, suggesting near-term optimism.
Insider Participation
4 insider sellers vs. 3 buyers. More insiders selling than buying suggests cautious or negative sentiment.
No Dividend Yield Data
CGTX has not reported any dividend yield values in the available annual periods.
cgtx Dividend History
Learning Layer
Related Guides
Build conviction on CGTX by pairing this stock hub with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.